Venrock
VC Fund
Palo Alto, United States
Venrock is a VC fund in Palo Alto focused on Health Care and Biotechnology. Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare, and Tudou.
- Total investments:
- 610
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $500M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Venrock invests in
Stages Venrock invests in
Countries Venrock invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 16 contacts → | |||
Round size
- Series A
- $3.5M–$50M
- Series B
- $9.5M–$85M
- Series C
- $11M–$104M
Investment Focus
Industry
- Health Care 90 (15%)
- Biotechnology 85 (14%)
- Software 61 (10%)
- Medical 45 (7%)
- Information Technology 37 (6%)
Stage
- Series B 120 (20%)
- Series A 113 (19%)
- Series C 89 (15%)
- Series D 52 (9%)
- Seed 50 (8%)
Country
- United States 278 (46%)
- United Kingdom 4 (1%)
- Canada 3 (0%)
- Israel 3 (0%)
- Switzerland 3 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Gottesdiener
Partner
|
Partner | Total investments: 3 | Find email | |
Anthony Evnin
Partner Emeritus
|
Partner Emeritus | Total investments: 17 | Find email | |
Bryan Roberts
Partner
|
Partner | Total investments: 66 | Find email | |
Mariana Mihalusova
Vice President
|
Vice President | Total investments: 3 | Find email | |
Mike Tyrrell
General Partner
|
General Partner | Total investments: 24 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improvethe therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics. | $350M / Post-IPO Equity / Oct 13, 2026 | ||
| Suki is an AI-powered, voice-enabled digital assistant for doctors. It was designed to help healthcare organizations with their administrative tasks. Suki helps physicians in dictating notes, retrieving info, and works with EHR. The company was founded in 2017 and is headquartered in Redwood City, California. | $90M / Series E / Oct 12, 2026 | ||
| Carbon Recycle Technologies is a renewable energy company producing bio-methanol and green hydrogen. | $50K / Venture - Series Unknown / Oct 07, 2026 | ||
| Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovasculardisease, enabling medical practitioners to treat patients and improve their lives. | $275M / Series F / Sep 09, 2026 | ||
| Aligned Marketplace connects self-insured employers with independent advanced primary and specialty care providers. | $20M / Series A / Aug 13, 2026 | ||
| Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | ||
| Arca is an AI-native wealth management firm that pairs human financial advisors with purpose-built AI agents to deliver highly personalized, scalable advice for high-net-worth and growing clients. The company runs an integrated platform that automates operational work | $48.5M / Series A / Jun 25, 2026 | ||
| cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M / Series A / May 20, 2026 | ||
| GenLogs is a freight intelligence company that offers truck carrier mapping services via AI-driven roadside sensors. | $60M / Series B / Feb 02, 2026 | ||
| FINNY is an AI prospecting tool that provides technology solutions for financial advisors. | $17M / Series A / Dec 18, 2025 | ||
| See all 610 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Venrock invest in?
Venrock invests primarily in Health Care, Biotechnology and Software startups, most often at Series B and Series A stage. Most of the 610 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Venrock invest in?
Venrock typically joins rounds of $3.5M–$50M at Series A, $9.5M–$85M at Series B and $11M–$104M at Series C. These are whole funding-round sizes, not Venrock's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Venrock took part in.
How do I contact Venrock?
Public channels for Venrock include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Venrock?
The team at Venrock includes Andrew Gottesdiener (Partner), Anthony Evnin (Partner Emeritus) and Bryan Roberts (Partner), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
